CANTON, Mass., Feb. 17, 2022 (GLOBE NEWSWIRE) — Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today announced the appointment of Michael J. Driscoll, Ed.D. to the Company’s Board of Directors, effective February 15, 2022. Dr. Driscoll will serve as an independent director of the Company and member of the Audit Committee and the Nominating Committee of the Board.
“I am pleased to welcome Dr. Driscoll to our Board of Directors following a 28-year career in the financial services industry, as well as 10 years in academia as a business school professor and dean,” said Gary S. Gillheeney, Sr., President and Chief Executive Officer of Organogenesis. “Dr. Driscoll brings a wealth of business and finance related knowledge and I look forward to his strategic insights and contributions.”
Dr. Driscoll most recently served as the dean of the Richard J. Bolte, Sr. School of Business at Mount St. Mary’s University from 2018 to 2020. He was previously a Clinical Professor and Senior Executive in Residence for the Robert B. Willumstad School of Business at Adelphi University from 2010 to 2018. Prior to his career in education, Dr. Driscoll worked for 28 years in the financial services industry. Among his career highlights during this period, he served as the Global Head of Trading for Geosphere Capital LLC, a hedge fund focused on global natural resources and industrials, from 2007 to 2010 and as a Senior Managing Director of Equity Trading at Bear, Stearns & Co. Inc., a global investment bank, from 2002 to 2007. Dr. Driscoll holds an Ed.D. in Higher Education Management from the University of Pennsylvania, an MBA in International Business from Adelphi University and a B.S. in Management and Marine Transportation from the State University of New York Maritime College.
About Organogenesis Holdings Inc.
Organogenesis Holdings Inc. is a leading regenerative medicine company offering a portfolio of bioactive and acellular biomaterials products in advanced wound care and surgical biologics, including orthopedics and spine. Organogenesis’s comprehensive portfolio is designed to treat a variety of patients with repair and regenerative needs. For more information, visit www.organogenesis.com.
